D2R (DNA to RNA) is a research initiative at McGill that is positioning Canada as a global leader in RNA-based therapies, revolutionizing treatments for rare and infectious diseases, and cancer.
With a landmark $165 million investment from the Government of Canada, D2R is advancing cutting-edge science and building powerful collaborations across academia, industry, and different communities to ensure that life-saving therapies are accessible to all, especially equity-deserving populations.